Nyt fra tidsskrifterne
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Ingen søgeord valgt.
44 emner vises.
Journal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background Admission and discharge screening of patients for asymptomatic gut colonization with multidrug-resistant organisms (MDROs) is a traditional approach to active surveillance, but its sensitivity for detecting colonization is uncertain.Methods Daily rectal or fecal swab samples and clinical data were collected over 12 months from patients in one 25-bed intensive care unit (ICU) in Chicago, IL USA and tested for the following multidrug-resistant organisms (MDROs): vancomycin-resistant enterococci (VRE); third-generation cephalosporin-resistant Enterobacterales, including extended-spectrum β-lactamase-producing Enterobacterales (ESBL); and carbapenem-resistant Enterobacterales (CRE). MDRO detection by (1) admission/discharge surveillance cultures or (2) clinical cultures were compared to daily surveillance cultures. Samples underwent 16S rRNA gene sequencing to measure the relative abundance of operational taxonomic units (OTUs) corresponding to each MDRO.Results Compared with daily surveillance cultures, admission/discharge cultures detected 91% of prevalent MDRO colonization and 63% of incident MDRO colonization among medical ICU patients. Only a minority (7%) of MDRO carriers were identified by clinical cultures. Higher relative abundance of MDRO-associated OTUs and specific antibiotic exposures were independently associated with higher probability of MDRO detection by culture.Conclusion Admission and discharge surveillance cultures underestimated MDRO acquisitions in an ICU. These limitations should be considered when designing sampling strategies for epidemiologic studies that use culture-based surveillance.
Læs mere Tjek på PubMedJournal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background Bone infections from Staphylococcus aureus are notoriously difficult to treat and have high recurrence rates. Local antibiotic delivery systems hold the potential to achieve high in situ antibiotic concentrations, which are otherwise challenging to achieve via systemic administration. Existing solutions have been shown to confer suboptimal drug release and distribution. Here we present and evaluate an injectable in situ-forming depot system termed CarboCell. The CarboCell technology provides sustained and tuneable release of local high-dose antibiotics.Methods CarboCell formulations of levofloxacin or clindamycin with or without antimicrobial adjuvants cis-2-decenoic acid or cis-11-methyl-2-dodecenoic acid were tested in experimental rodent and porcine implant-associated osteomyelitis models. In the porcine models, debridement and treatment with CarboCell-formulated antibiotics was carried out without systemic antibiotic administration. The bacterial burden was determined by quantitative bacteriology.Results CarboCell formulations eliminated S. aureus in infected implant rat models. In the translational implant-associated pig model, surgical debridement, and injection of clindamycin-releasing CarboCell formulations resulted in pathogen-free bone tissues and implants in 9/12, and full eradication in 5/12 pigs.Conclusions Sustained release of antimicrobial agents mediated by the CarboCell technology demonstrated promising therapeutic efficacy in challenging translational models and may be beneficial in combination with the current standard of care.
Læs mere Tjek på PubMedJournal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background The global incidence target for the elimination of hepatitis C among people who inject drugs (PWID) is
Læs mere Tjek på PubMedJournal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Concerns regarding toxicity and resistance of current drugs have been reported in visceral leishmaniasis. Anti-microbial peptides are considered as new promising candidates and amongst them, human cathelicidin hCAP18/LL-37 showed significant parasite killing on drug-sensitive and resistant Leishmania promastigotes, coupled with its apoptosis-inducing role. Administration of hCAP18/LL-37 in infected macrophages also decreased parasite survival and increased the host favorable cytokine IL-12. However, 1,25-dihydroxyvitamin D3 (VitD3)-induced endogenous hCAP18/LL-37 production was hampered in infected THP-1 cells. Infection also suppressed the VitD3-receptor (VDR), transcription factor of hCAP18/LL-37. cAMP response element modulator (CREM), the repressor of VDR, was induced in infection resulting in suppression of both VDR and cathelicidin expression. PGE2/cAMP/PKA axis was found to regulate CREM induction during infection and silencing CREM in infected cells and BALB/c mice led to decreased parasite survival. Present study thus documents the anti-leishmanial potential of cathelicidin and further identifies CREM as a repressor of cathelicidin in Leishmania infection.
Læs mere Tjek på PubMedRui GaoXinxin XuPrashant KumarYe LiuHongyu ZhangXiao GuoMaozhong SunFelippe Mariano ColombariAndré F. de MouraChanglong HaoJessica MaEmine Sumeyra Turali EmreMinjeong ChaLiguang XuHua KuangNicholas A. KotovChuanlai XuaInternational Joint Research Laboratory for Biointerface and Biodetection, School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, People’s Republic of ChinabState Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, People’s Republic of ChinacDepartment of Materials Science and Engineering, University of Michigan, Ann Arbor, MI 48109dDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109eBiointerfaces Institute, University of Michigan, Ann Arbor, MI 48109fInstitute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan 650000, People’s Republic of ChinagBrazilian Biorenewables National Laboratory, Brazilian Center for Research in Energy and Materials, Campinas, São Paulo 13083-100, BrazilhDepartment of Chemistry, Federal University of São Carlos, São Carlos, São Paulo 13565-905, BraziliNSF Center for Complex Particles and Particle Systems (COMPASS), University of Michigan, Ann Arbor, MI 48109
Proceedings of the National Academy of Sciences, 28.03.2024
Tilføjet 28.03.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 13, March 2024.
Læs mere Tjek på PubMedStefania D’AriaCéline MaquetShuang LiSuveera DhupAnouk LepezArnaud KohlerVincent F. Van HéeRajesh K. DadhichMarine FrenièreFabienne AndrisIvan NemazanyyPierre SonveauxBénédicte MachielsLaurent GilletMichel Y. BraunaInstitute for Medical Immunology, Faculty of Medicine, Université libre de Bruxelles, Gosselies 6041, BelgiumbImmunology-Vaccinology, Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine - Fundamental and Applied Research for Animals & Health Research Unit, University of Liège, Liège 4000, BelgiumcPole of Pharmacology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels 1200, BelgiumdImmunobiology Laboratory, Faculty of Sciences, Université libre de Bruxelles, Gosselies 6041, BelgiumePlateforme d’étude du métabolisme, Institut Necker, Inserm US 24 - CNRS UMS 3633, Faculté de Médecine Paris Descartes, Paris 75015, FrancefWEL Research Institute, Welbio Department, Wavre 1300, Belgium
Proceedings of the National Academy of Sciences, 28.03.2024
Tilføjet 28.03.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 13, March 2024.
Læs mere Tjek på PubMedAmruta A. KarbelkarMaria FontT. Jarrod SmithHolger SondermannGeorge A. O’TooleaDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755bCSSB Centre for Structural Systems Biology, Deutsches Elektronen-Synchrotron DESY, D-22607 Hamburg, Germany
Proceedings of the National Academy of Sciences, 28.03.2024
Tilføjet 28.03.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 13, March 2024.
Læs mere Tjek på PubMedFlorian FleckensteinSimon StephanHans HasseaLaboratory of Engineering Thermodynamics, Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau (RPTU), Kaiserslautern 67663, Germany
Proceedings of the National Academy of Sciences, 28.03.2024
Tilføjet 28.03.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 13, March 2024.
Læs mere Tjek på PubMedTakafumi ShichijoJun-ichirou YasunagaKei SatoKisato NosakaKosuke ToyodaMiho WatanabeWenyi ZhangYoshio KoyanagiEdward L. MurphyRoberta L. BruhnKi-Ryang KohHirofumi AkariTerumasa IkedaReuben S. HarrisPatrick L. GreenMasao MatsuokaaDepartment of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, JapanbLaboratory of Virus Control, Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, JapancDivision of Systems Virology, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, JapandCore Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, Saitama 332-0012, JapaneLaboratory of Systems Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, JapanfDepartment of Laboratory Medicine, University of California, San Francisco 94158gDepartment of Epidemiology/Biostatistics, University of California, San FranciscohVitalant Research Institute, San Francisco 94105iDepartment of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka 545-0053, JapanjCenter for the Evolutionary Origins of Human Behavior, Kyoto University, Inuyama, Aichi 484-8506, JapankDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, JapanlDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229mHHMI, University of Texas Health San Antonio, San Antonio, TX 78229nCenter for Retrovirus Research, Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210oDepartment of Veterinary Biosciences, The Ohio State University, Columbus, OH
Proceedings of the National Academy of Sciences, 28.03.2024
Tilføjet 28.03.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 13, March 2024.
Læs mere Tjek på PubMedHanna Kehlet-DelgadoAngeliqua P. MontoyaKyson T. JensenCamille E. WendlandtChristopher DexheimerMiles RobertsLorena Torres MartínezMaren L. FriesenJoel S. GriffittsStephanie S. PorteraDepartment of Plant Pathology, Washington State University, Pullman, WA 99164bSchool of Biological Sciences, Washington State University, Vancouver, WA 98686cDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602dDepartment of Biology, St. Mary’s College of Maryland, St. Mary’s City, MD 20686-3001eDepartment of Crop and Soil Sciences, Washington State University, Pullman, WA 99164
Proceedings of the National Academy of Sciences, 28.03.2024
Tilføjet 28.03.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 13, March 2024.
Læs mere Tjek på PubMedMichael SheinmanPeter F. ArndtFlorian MassipaInstitute for Advanced Studies, Sevastopol State University, Sevastopol 299053, CrimeabDepartment of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin 12163, GermanycDepartment U900, Centre for Computational Biology, Mines Paris, PSL University, Paris 75006, FrancedDepartment U900, Institut Curie, Université Paris Sciences et Lettres, Paris 75005, FranceeINSERM, U900, Paris 75005, France
Proceedings of the National Academy of Sciences, 28.03.2024
Tilføjet 28.03.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 13, March 2024.
Læs mere Tjek på PubMedClinical Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Introduction A surge of human influenza A(H7N9) cases began in 2016 in China due to an antigenically distinct lineage. Data are needed about the safety and immunogenicity of 2013 and 2017 A(H7N9) inactivated influenza vaccines (IIVs) and the effects of AS03 adjuvant, prime-boost interval, and priming effects of 2013 and 2017 A(H7N9) IIVs.Methods Healthy adults (n=180), ages 19–50 years, were enrolled into this partially-blinded, randomized, multi-center Phase 2 clinical trial. Participants were randomly assigned to 1 of 6 vaccination groups evaluating homologous versus heterologous prime-boost strategies with two different boost intervals (21 versus 120 days) and two dosages (3.75 or 15 μg of hemagglutinin) administered with or without AS03 adjuvant. Reactogenicity, safety, and immunogenicity measured by hemagglutination inhibition (HAI) and neutralizing antibody titers were assessed.Results Two doses of A(H7N9) IIV were well tolerated, and no safety issues were identified. Although most participants had injection site and systemic reactogenicity, these symptoms were mostly mild to moderate in severity; injection site reactogenicity was greater in vaccination groups receiving adjuvant. Immune responses were greater after an adjuvanted second dose, and with a longer interval between prime and boost. The highest HAI GMT (95%CI) observed against the 2017 A(H7N9) strain was 133.4 (83.6, 212.6) among participants who received homologous, adjuvanted 3.75 ug+AS03/2017 doses with delayed boost interval.Conclusions Administering AS03 adjuvant with the second H7N9 IIV dose and extending the boost interval to 4 months resulted in higher peak antibody responses. These observations can broadly inform strategic approaches for pandemic preparedness. (NCT03589807)
Læs mere Tjek på PubMedClinical Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background Improved epidemiologic and treatment data for active tuberculosis (TB) with chronic hepatitis B virus (cHBV) infection might inform and encourage screening and vaccination programs focused on persons at risk of having both conditions.Methods We matched the California Department of Public Health TB registry during 2016–2020 to the cHBV registry using probabilistic matching algorithms. We used chi-square analysis to compare the characteristics of persons with TB and cHBV with those with TB only. We compared TB treatment outcomes between these groups using modified Poisson regression models. We calculated the time between reporting of TB and cHBV diagnoses for those with both conditions.Results We identified 8,435 persons with TB, including 316 (3.7%) with cHBV. Among persons with TB and cHBV, 256 (81.0%) were non-U.S.-born Asian vs 4,186 (51.6%) with TB only (P 60 days after cHBV (median 3,411 days).Conclusion Persons with TB and cHBV were found more frequently in certain groups compared with TB only, and infrequently had their conditions diagnosed together. This highlights an opportunity to improve screening and treatment of TB and cHBV in those at high risk for coinfection.
Læs mere Tjek på PubMedClinical Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background There are little data on changes in insulin sensitivity during the first few years of life following in utero human immunodeficiency virus (HIV) and antiretroviral (ARV) exposure.Methods The Tshilo Dikotla study enrolled pregnant persons with HIV (PWH) (receiving tenofovir/emtricitabine or lamivudine plus dolutegravir or efavirenz) and pregnant individuals without HIV, as well as their liveborn children. Newborns were randomized to receive either zidovudine (AZT) or nevirapine (NVP) postnatal prophylaxis. Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) was assessed at birth and 1, 18, 24, and 36 months of life. We fit linear mixed-effects models to evaluate the association between in utero HIV/ARV exposure and average HOMA-IR from birth through 36 months of life, adjusting for confounders.Results A total of 419 children were included (287 with in utero HIV/ARV exposure and uninfected [CHEU] and 132 without in utero HIV/ARV exposure [CHUU]). CHEU were born to older women (29.6 vs 25.3 years of age) with higher gravidity (3 vs 1). HOMA-IR was persistently higher in CHEU versus CHUU in adjusted analyses (mean difference of 0.07 in log10 HOMA-IR, P = .02) from birth through 36 months of life. Among CHEU, no differences in HOMA-IR were observed from birth through 36 months by in utero ARV exposure status or between AZT and NVP infant prophylaxis arms.Conclusions In utero HIV/ARV exposure was associated with lower insulin sensitivity throughout the first 36 months of life, indicating persistent early life metabolic disturbances which may raise concern for poorer metabolic health later in life.
Læs mere Tjek på PubMedMinh Ha NgoJoshua PankracRyan C. Y. HoEmmanuel NdashimyeRahul PawaRenata CeccacciTsigereda BiruAbayomi S. OlabodeKatja KleinYue LiColin KovacsRobert AssadJeffrey M. JacobsonDavid H. CanadayStephen TomusangeSamiri JamiruAggrey AnokTaddeo KityamuweesiPaul BuuleRonald M. GaliwangoSteven J. ReynoldsThomas C. QuinnAndrew D. ReddJessica L. ProdgerJamie F. S. MannEric J. Artsa Department of Microbiology and Immunology, University of Western Ontario, London, Canadab College of Veterinary Medicine, Vietnam National University of Agriculture, Hanoi, Vietnamc Special Immunology Unit and Division of Infectious Diseases, Department of Medicine, Case Western Reserve University, Cleveland, OH, USAd Bristol Veterinary School, University of Bristol, Bristol, UKe Maple Leaf Medical Clinic and Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Canadaf Rakai Health Sciences Program, Kalisizo, Ugandag Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USAh Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Emerg Microbes Infect, 28.03.2024
Tilføjet 28.03.2024
Qianchun GongRendi JiangLina JiHaofeng LinMeiqin LiuXiaofang TangYong YangWei HanJing ChenZishuo GuoQi WangQian LiXi WangTingting JiangShizhe XieXinglou YangPeng ZhouZhengli ShiXinhua Lina State Key Laboratory of Genetic Engineering, Greater Bay Area Institute of Precision Medicine (Guangzhou), School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of Chinab Joint Laboratory for Lung Development and Related Diseases of West China Second University Hospital, Sichuan University and School of Life Sciences of Fudan University, Chengdu, People’s Republic of Chinac School of Life Sciences, Inner Mongolia University, Hohhot, People’s Republic of Chinad State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of Chinae The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of Chinaf Guangzhou Laboratory, Guangzhou International Bio Island, Guangzhou, People’s Republic of Chinag Yunnan Key Laboratory of Biodiversity Information, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, People’s Republic of China
Emerg Microbes Infect, 28.03.2024
Tilføjet 28.03.2024
Ying LiuJiayou ZhangWen LiuYongbing PanShunan RuanXuanxuan NianWei ChenLina SunQiangling YinXin YueQingliang LiFang GuiCong WuShuzhen WangYunkai YangZhaofei JingFeiguang LongZejun WangZeyu ZhangChaolin HuangKai DuanMifang LiangXiaoming Yanga Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of Chinab Hubei Clinical Research Center for Infectious Diseases, Wuhan, People’s Republic of Chinac Hubei Public Health Clinical Center, Wuhan, People’s Republic of Chinad Wuhan Research Center for Communicable Disease Diagnosis and Treatment, Wuhan, People’s Republic of Chinae National Engineering Technology Research Center for Combined Vaccines, Wuhan, People’s Republic of Chinaf Wuhan Institute of Biological Products Co. Ltd., Wuhan, People’s Republic of Chinag National Institute for Viral Disease Control and Prevention, Chinese CDC, Beijing, People’s Republic of Chinah Hubei Provincial Center for Disease Control and Prevention, Wuhan, People’s Republic of Chinai China National Biotec Group Company Limited, Beijing, People’s Republic of China
Emerg Microbes Infect, 28.03.2024
Tilføjet 28.03.2024
Jiahui GuoYinan LaiZhixiang YangWenbo SongJunwei ZhouZhuang LiWen SuShaobo XiaoLiurong Fanga National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of Chinab Key Laboratory of Preventive Veterinary Medicine in Hubei Province, The Cooperative Innovation Center for Sustainable Pig Production, Wuhan, People’s Republic of Chinac Hubei Hongshan Laboratory, Huazhong Agricultural University, Wuhan, People’s Republic of China
Emerg Microbes Infect, 28.03.2024
Tilføjet 28.03.2024
Morgan Brisse, Hinh Ly
Journal of Medical Virology, 28.03.2024
Tilføjet 28.03.2024
Minsoo Kim, Eunjung Kim
Journal of Medical Virology, 28.03.2024
Tilføjet 28.03.2024
Shaoli Lin, Xiaochun Wang, Bhargava Teja Sallapalli, Adam Hage, Peixi Chang, Jia He, Sonja M. Best, Yanjin Zhang
Journal of Medical Virology, 28.03.2024
Tilføjet 28.03.2024
Journal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Introduction Establishing the safety and immunogenicity of a hepatitis E virus vaccine in multiple populations could facilitate broader access and prevent maternal and infant mortality.Methods We conducted a phase 1, randomized, double-blinded, placebo-controlled (4:1 vaccine: placebo) trial of 30 µg HEV-239 (Hecolin®, Xiamen Innovax Biotech Company Limited, China) administered intramuscularly in healthy US adults aged 18-45 years. Participants were vaccinated on days 1, 29, and 180. Participants reported solicited local and systemic reactions for 7 days following vaccination and were followed through 12 months after enrollment for safety and immunogenicity (IgG, IgM).Results Solicited local and systemic reactions between treatment and placebo group were similar and overall mild. No participants experienced serious adverse events related to HEV-239. All participants receiving HEV-239 seroconverted at one month following the first dose and remained seropositive throughout the study. HEV-239 elicited a robust hepatitis E IgG response that peaked one month following the second dose (Geometric Mean Concentration (GMC) 6.16; 95% CI 4.40-8.63), was boosted with the third dose (GMC 11.50; 95% CI 7.90-16.75) and persisted through 6 months.Conclusions HEV-239 is safe and elicits a durable immune response through at least 6 months after the third dose in healthy US adults.Clinical Trials Registration NCT03827395. Safety Study of Hepatitis E Vaccine (HEV239) - Full Text View - ClinicalTrials.gov
Læs mere Tjek på PubMedJournal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract The Centers for Disease Control estimates antibiotic-associated pathogens result in 2.8 million infections and 38,000 deaths annually in the United States. This study applies species distribution modeling to elucidate the impact of environmental determinants of human infectious disease in an era of rapid global change. We modeled methicillin-resistant Staphylococcus aureus and Clostridioides difficile using 31 publicly accessible bioclimatic, healthcare, and sociodemographic variables. Ensemble models were created from 8 unique statistical and machine learning algorithms. Using International Classification of Diseases, 10th Edition codes, we identified 305,528 diagnoses of methicillin-resistant S.aureus and 302,001 diagnoses of C.difficile presence. Three environmental factors – average maximum temperature, specific humidity, and agricultural land density – emerged as major predictors of increased methicillin-resistant S.aureus and C.difficile presence; variables representing healthcare availability were less important. Species distribution modeling may be a powerful tool for identifying areas at increased risk for disease presence and have important implications for disease surveillance systems.
Læs mere Tjek på PubMedJournal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background GWAS have identified several non-functional tagSNPs associated with severe malaria. We hypothesized that causal SNPs could play a significant role in severe malaria by altering promoter or enhancer activity. Here, we sought to identify such regulatory SNPs.Methods SNPs in linkage disequilibrium with tagSNPs associated with severe malaria were identified and were further annotated using FUMA. Then, SNPs were prioritized using IW-scoring method to identify regulatory ones. Gene reporter assays were performed to assess the regulatory effect of a region containing candidates. The association between SNPs and severe malaria was assessed using logistic regression models in a Senegalese cohort.Results Among 418 SNPs, the best candidates were rs116525449 and rs79644959, which were in full disequilibrium between them, and located within the ARL14 promoter. Our gene reporter assay results revealed that the region containing the SNPs exhibited cell-specific promoter or enhancer activity, while the SNPs influenced promoter activity. We detected an association between severe malaria and those two SNPs using the overdominance model and we replicated the association of severe malaria with the tagSNP rs116423146.Conclusions We suggest that these SNPs regulate ARL14 expression in immune cells and the presentation of antigens to T lymphocytes, thus influencing severe malaria development.
Læs mere Tjek på PubMedJournal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Escherichia coli K1 is the leading cause of neonatal Gram-negative bacterial meningitis, but the pathogenesis of E. coli K1 meningitis remains unclear. Blood-brain barrier (BBB) penetration is a crucial step in E. coli meningitis development. Here, we uncovered the crucial role of CsiR, a GntR family regulator, in E. coli K1 virulence. During infection, csiR expression was induced due to the derepression by Fur in the blood and human brain microvascular endothelial cells (HBMECs). CsiR positively regulated ilvB expression, which is associated with branched chain amino acid synthesis. Furthermore, we revealed that IlvB activated the FAK/PI3 K pathway of HBMECs to induce actin cytoskeleton rearrangements, thereby promoting the bacterial invasion and penetration of the BBB. Overall, this study reveals a CsiR-mediated virulence regulation pathway in E. coli K1, which may provide a useful target for the prevention or therapy of E. coli meningitis.
Læs mere Tjek på PubMedJournal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background SARS-CoV-2 antigen-detection rapid diagnostic tests (Ag-RDTs) have become widely utilized but longitudinal characterization of their community-based performance remains incompletely understood.Methods This prospective longitudinal study at a large public university in Seattle, WA utilized remote enrollment, online surveys, and self-collected nasal swab specimens to evaluate Ag-RDT performance against real-time reverse transcription polymerase chain reaction (rRT-PCR) in the context of SARS-CoV-2 Omicron. Ag-RDT sensitivity and specificity within 1 day of rRT-PCR were evaluated by symptom status throughout the illness episode and Orf1b cycle threshold (Ct).Results From February to December 2022, 5,757 participants reported 17,572 Ag-RDT results and completed 12,674 rRT-PCR tests, of which 995 (7.9%) were rRT-PCR-positive. Overall sensitivity and specificity were 53.0% (95% CI: 49.6–56.4%) and 98.8% (98.5–99.0%), respectively. Sensitivity was comparatively higher for Ag-RDTs used 1 day after rRT-PCR (69.0%), 4 to 7 days post-symptom onset (70.1%), and Orf1b Ct ≤20 (82.7%). Serial Ag-RDT sensitivity increased with repeat testing ≥2 (68.5%) and ≥4 (75.8%) days after an initial Ag-RDT-negative result.Conclusion Ag-RDT performance varied by clinical characteristics and temporal testing patterns. Our findings support recommendations for serial testing following an initial Ag-RDT-negative result, especially among recently symptomatic persons or those at high-risk for SARS-CoV-2 infection.
Læs mere Tjek på PubMedJournal of Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background Streptococcus pneumoniae serotype 3 remains a problem globally. Malawi introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2011, but there has been no direct protection against serotype 3 carriage. We explored whether vaccine escape by serotype 3 is due to clonal expansion of a lineage with a competitive advantage.Methods The distribution of serotype 3 Global Pneumococcal Sequence Clusters (GPSCs) and sequence types (STs) globally was assessed using sequences from the Global Pneumococcal Sequencing Project. Whole-genome sequences of 135 serotype 3 carriage isolates from Blantyre, Malawi (2015–2019) were analyzed. Comparative analysis of the capsule locus, entire genomes, antimicrobial resistance, and phylogenetic reconstructions were undertaken. Opsonophagocytosis was evaluated using serum samples from vaccinated adults and children.Results Serotype 3 GPSC10-ST700 isolates were most prominent in Malawi. Compared with the prototypical serotype 3 capsular polysaccharide locus sequence, 6 genes are absent, with retention of capsule polysaccharide biosynthesis. This lineage is characterized by increased antimicrobial resistance and lower susceptibility to opsonophagocytic killing.Conclusions A serotype 3 variant in Malawi has genotypic and phenotypic characteristics that could enhance vaccine escape and clonal expansion after post-PCV13 introduction. Genomic surveillance among high-burden populations is essential to improve the effectiveness of next-generation pneumococcal vaccines.
Læs mere Tjek på PubMedPatrick D.J. Sturm, Noud T.H. Hermans, Adri G.M. van der Zanden, Cas J.A. Peters, Tanja Schülin
Clinical Microbiology and Infection, 28.03.2024
Tilføjet 28.03.2024
To investigate the prevalence of ampicillin resistance in H. influenzae and the diagnostic accuracy of the EUCAST recommended disc diffusion method to detect the increasingly prevalent ampicillin resistance due to the presence of PBP3 alterations based on mutations in the ftsI gene.
Læs mere Tjek på PubMedBMC Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background There are abundant studies on COVID-19 but few on its impact on hepatitis E. We aimed to assess the effect of the COVID-19 countermeasures on the pattern of hepatitis E incidence and explore the application of time series models in analyzing this pattern. Methods Our pivotal idea was to fit a pre-COVID-19 model with data from before the COVID-19 outbreak and use the deviation between forecast values and actual values to reflect the effect of COVID-19 countermeasures. We analyzed the pattern of hepatitis E incidence in China from 2013 to 2018. We evaluated the fitting and forecasting capability of 3 methods before the COVID-19 outbreak. Furthermore, we employed these methods to construct pre-COVID-19 incidence models and compare post-COVID-19 forecasts with reality. Results Before the COVID-19 outbreak, the Chinese hepatitis E incidence pattern was overall stationary and seasonal, with a peak in March, a trough in October, and higher levels in winter and spring than in summer and autumn, annually. Nevertheless, post-COVID-19 forecasts from pre-COVID-19 models were extremely different from reality in sectional periods but congruous in others. Conclusions Since the COVID-19 pandemic, the Chinese hepatitis E incidence pattern has altered substantially, and the incidence has greatly decreased. The effect of the COVID-19 countermeasures on the pattern of hepatitis E incidence was temporary. The incidence of hepatitis E was anticipated to gradually revert to its pre-COVID-19 pattern.
Læs mere Tjek på PubMedBMC Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background The burden of cervical cancer in Ghana is high due to a lack of a national screening and vaccination program. Geographical variations in high-risk Human Papilloma Virus incidence and type should be considered for vaccine improvement and screening in LMICs. Methods A descriptive, multi-center cross-sectional study with purposive sampling of cases with cervical cancer diagnosed from January 2012 through to December 2018 was employed relying on archived Formalin Fixed Paraffin Embedded (FFPE) tissues from four (4) Teaching Hospitals. Cervical cancers were assessed for histopathological features following WHO guidelines. In addition, the novel Tumour Budding and Nest Size Grade (TBNS) for SCC, SILVA pattern of invasion for EAC and Tumour Infiltrating Lymphocytes (TILs) were assessed. High Risk HPV testing was performed using an isothermal, multiplex nucleic acid amplification method from ATILA biosystem (Mountain View California, USA). The FFPE blocks were tested for 15 hrHPV genotypes. Results were analyzed using SPSS v.26.0, with descriptive statistics and cross-tabulation and chi-square tests done with significance established at p
Læs mere Tjek på PubMedBMC Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background This real-world study assessed the epidemiology and clinical complications of Clostridioides difficile infections (CDIs) and recurrences (rCDIs) in hospital and community settings in Germany from 2015 − 2019. Methods An observational retrospective cohort study was conducted among adult patients diagnosed with CDI in hospital and community settings using statutory health insurance claims data from the BKK database. A cross-sectional approach was used to estimate the annual incidence rate of CDI and rCDI episodes per 100,000 insurants. Patients’ demographic and clinical characteristics were described at the time of first CDI episode. Kaplan-Meier method was used to estimate the time to rCDIs and time to complications (colonic perforation, colectomy, loop ileostomy, toxic megacolon, ulcerative colitis, peritonitis, and sepsis). A Cox model was used to assess the risk of developing complications, with the number of rCDIs as a time-dependent covariate. Results A total of 15,402 CDI episodes were recorded among 11,884 patients. The overall incidence of CDI episodes declined by 38% from 2015 to 2019. Most patients (77%) were aged ≥ 65 years. Around 19% of CDI patients experienced at least one rCDI. The median time between index CDI episode to a rCDI was 20 days. The most frequent complication within 12-months of follow-up after the index CDI episode was sepsis (7.57%), followed by colectomy (3.20%). The rate of complications increased with the number of rCDIs. The risk of any complication increased by 31% with each subsequent rCDI (adjusted hazard ratio [HR]: 1.31, 95% confidence interval: 1.17;1.46). Conclusions CDI remains a public health concern in Germany despite a decline in the incidence over recent years. A substantial proportion of CDI patients experience rCDIs, which increase the risk of severe clinical complications. The results highlight an increasing need of improved therapeutic management of CDI, particularly efforts to prevent rCDI.
Læs mere Tjek på PubMedBMC Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Background The prevalence and distinction between first Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and reinfection with the Omicron variant among healthcare workers (HCWs) remain unclear. Methods A cross-sectional study was conducted at a hospital in Southern China. The study included 262 HCWs who were infected with SARS-CoV-2 between April and June 2023, with 101 cases of first infection and 161 ones of reinfection. Student’s t-test, Analysis of Variance (ANOVA), and Mann-Whitney U tests were used based on the distribution of quantitative variables. Pearson’s chi-square and Fisher’s exact tests were used based on the expected frequencies of categorical variables. Results The reinfection rate among HCWs was 11.5% (161/1406). The majority of the infected HCWs were female (212/262, 80.9%, first infection vs. reinfection: 76.2% vs. 83.9%). The nursing staff, had the highest percentage of SARS-CoV-2 infection (42.0%), especially of its reinfection (47.8%). Out of the 262 infected individuals, 257 had received SARS-CoV-2 vaccination, primarily inactivated vaccines (243/257, 91.1%). The first infection group, which received four doses (24, 23.8%), was significantly higher than that in the reinfection group (6, 3.7%) (P
Læs mere Tjek på PubMedAlice Cortesi, Francesco Gandolfi, Fabiana Arco, Pierluigi Di Chiaro, Emanuele Valli, Sara Polletti, Roberta Noberini, Francesco Gualdrini, Sergio Attanasio, Francesca Citron, I-lin Ho, Rutvi Shah, Er-Yen Yen, Mara Cetty Spinella, Simona Ronzoni, Simona Rodighiero, Nico Mitro, Tiziana Bonaldi, Serena Ghisletti, Silvia Monticelli, Andrea Viale, Giuseppe Riccardo Diaferia, Gioacchino Natoli
Science Advances, 28.03.2024
Tilføjet 28.03.2024
Julien Cayron, Thierry Oms, Tatjana Schlechtweg, Safia Zedek, Laurence Van Melderen
Science Advances, 28.03.2024
Tilføjet 28.03.2024
Alison A. Chomiak, Rochelle L. Tiedemann, Yanqing Liu, Xiangqian Kong, Ying Cui, Ashley K. Wiseman, Kate E. Thurlow, Evan M. Cornett, Michael J. Topper, Stephen B. Baylin, Scott B. Rothbart
Science Advances, 28.03.2024
Tilføjet 28.03.2024
Sangsin Lee, Seung Geun Song, Gwanghun Kim, Sehui Kim, Hyun Jung Yoo, Jaemoon Koh, Ye-Ji Kim, Jingwen Tian, Eunji Cho, Youn Soo Choi, Sunghoe Chang, Hyun Mu Shin, Kyeong Cheon Jung, Ji Hoon Kim, Tae Min Kim, Yoon Kyung Jeon, Hye Young Kim, Minho Shong, Ji Hyung Kim, Doo Hyun Chung
Science Advances, 28.03.2024
Tilføjet 28.03.2024
Carlo Polidori, Andrea Ferrari, Luigimaria Borruso, Paola Mattarelli, Maria Luisa Dindo, Monica Modesto, Marco Carrieri, Arianna Puggioli, Federico Ronchetti, Romeo Bellini
PLoS One Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
by Carlo Polidori, Andrea Ferrari, Luigimaria Borruso, Paola Mattarelli, Maria Luisa Dindo, Monica Modesto, Marco Carrieri, Arianna Puggioli, Federico Ronchetti, Romeo Bellini
Læs mere Tjek på PubMedErika Renzi, Valentina Baccolini, Antonio Covelli, Leonardo Maria Siena, Antonio Sciurti, Giuseppe Migliara, Azzurra Massimi, Carolina Marzuillo, Corrado De Vito, Leandro Casini, Antonio Angeloni, Ombretta Turriziani, Guido Antonelli, Fabrizio D’Alba, Antonella Polimeni, Collaborating Group, Paolo Villari
PLoS One Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
by Erika Renzi, Valentina Baccolini, Antonio Covelli, Leonardo Maria Siena, Antonio Sciurti, Giuseppe Migliara, Azzurra Massimi, Carolina Marzuillo, Corrado De Vito, Leandro Casini, Antonio Angeloni, Ombretta Turriziani, Guido Antonelli, Fabrizio D’Alba, Antonella Polimeni, Collaborating Group , Paolo Villari Background During the SARS-CoV-2 testing program offered through the RT-PCR test by Sapienza University of Rome, we conducted a test-negative case-control study to identify risk factors for acquiring SARS-CoV-2 infection among university students. Methods Each SARS-CoV-2-positive case detected was matched to two controls randomly selected from students who tested negative on the same day. 122 positive students and 244 negative students were enrolled in the study. Multivariable conditional logistic regression models were built. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated. A second model was limited to students who had attended campus. Results Out of 8223 tests for SARS-CoV-2, 173 students tested positive (2.1%), of whom 122 (71.5%) were included in the case-control study. In the first analysis, being a non-Italian student (aOR: 8.93, 95% CI: 2.71–29.41), having received only the primary vaccination course (aOR: 2.94, 95% CI: 1.24–6.96) compared to the booster dose, known exposure to a COVID-19 case or someone with signs/symptoms suggestive of COVID-19 (aOR: 6.51, 95% CI: 3.48–12.18), and visiting discos (aOR: 4.07, 95% CI: 1.52–10.90) in the two weeks before testing increased the likelihood of SARS-CoV-2 infection. Conversely, students attending in-person lectures on campus seemed less likely to become infected (aOR: 0.34, 95% CI: 0.15–0.77). No association was found with other variables. The results of the second model were comparable to the first analysis. Conclusions This study indicates that if universities adopt strict prevention measures, it is safe for students to attend, even in the case of an infectious disease epidemic.
Læs mere Tjek på PubMedLeann Blake, Patricia Tucker, Leigh M. Vanderloo
PLoS One Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
by Leann Blake, Patricia Tucker, Leigh M. Vanderloo Screen time for children under 5 is associated with various health risks. Amidst the COVID-19 pandemic, screen use among young children increased significantly. Mothers were more likely than fathers to be the primary caregivers and disproportionally assumed the responsibility of monitoring their children’s screen time. Several studies have examined children’s screen use throughout the pandemic; however, few have addressed mothers’ experiences. Therefore, the current study aimed to investigate mothers’ perceptions regarding the barriers and facilitators faced when trying to reduce their child’s pandemic screen time, as expressed on Reddit (a social media platform for anonymous discussion and information sharing). Two subreddit forums targeted toward mothers, \'mommit\' and \'beyondthebump,\' with 646,000 and 554,000 users, respectively, were examined. Posts were collected using related search terms and screened for inclusion by three independent researchers. Inductive thematic content analysis was leveraged to identify themes. In total, 582 posts were reviewed from March 14th, 2020, to August 31st, 2022. Qualitative analysis yielded 5 themes; 6 barriers and 2 facilitators were derived from themes and/or subthemes, where applicable. Results suggest that mothers faced barriers when trying to reduce their child’s screen time, including their competing work and in-home obligations, using screens to occupy their child during travel, child screen use with other caregivers, offering their child screen time while they needed rest, pandemic changes in routine, and using screens to encourage their child to engage in necessary behaviours. However, facilitating factors, including advice received from other mothers on how to reduce their child’s screen time and the sharing of non-screen alternatives supported mothers in lowering their children’s screen time. These results are important for future interventions, which may utilize the conclusions of this study to address what mothers perceive to be helping or hindering them, thus empowering mothers to successfully limit their children’s screen time.
Læs mere Tjek på PubMedAbhishek Padhi, Ashwini Agarwal, Mayuri Bhise, Anil Chaudhary, Krupal Joshi, C. D. S. Katoch
PLoS One Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
by Abhishek Padhi, Ashwini Agarwal, Mayuri Bhise, Anil Chaudhary, Krupal Joshi, C. D. S. Katoch Background Tuberculosis (TB) continues to pose a significant public health challenge in India, which is home to one of the highest TB burdens worldwide. This systematic review and meta-analysis will aim to synthesize the anticipated progress and potential challenges in achieving TB elimination in India by 2025. Methods A comprehensive search will be conducted across multiple databases, including PubMed, Scopus, and Web of Science, to identify relevant studies. The eligibility criteria will encompass individuals diagnosed with TB in India, interventions targeting TB treatment, prevention, or control, and various comparator groups. Outcomes of interest will include incidence reduction, mortality rate, treatment success rate, barriers to TB care, and more. Both quantitative and qualitative data will be synthesized, and the risk of bias will be assessed using established tools. Outcomes The review is expected to provide a holistic understanding of the TB landscape in India, highlighting the effective interventions and potential challenges in the journey towards TB elimination. Conclusions While it is anticipated that significant progress will be made in the fight against TB in India, challenges are likely to persist. This review will offer a comprehensive roadmap for researchers, policymakers, and healthcare professionals, emphasizing the importance of continued efforts, innovative strategies, and a multi-pronged approach in achieving the goal of TB elimination in India by 2025.
Læs mere Tjek på PubMedJelena Dimnjaković, Tamara Buble, Pero Ivanko, Tamara Poljičanin, Sandra Karanović Štambuk, Hana Brborović, Ognjen Brborović
PLoS One Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
by Jelena Dimnjaković, Tamara Buble, Pero Ivanko, Tamara Poljičanin, Sandra Karanović Štambuk, Hana Brborović, Ognjen Brborović Introduction Patients with diabetes mellitus type 2 and chronic kidney disease (T2DM-CKD) have a 5 times higher risk of developing severe SARS-CoV-2 infection than those without these 2 diseases. The goal of this study is to provide information on T2DM-CKD and COVID-19 outcomes, with an emphasis on the association with anti-diabetic medications. Methodology Study is designed as a retrospective cohort analysis covering the years 2020 and 2021. Data from the National Diabetes Registry (CroDiab) were linked to hospital data, primary healthcare data, Causes of Death Registry data, the SARS-CoV-2 vaccination database, and the SARS-CoV-2 test results database. Study outcomes were cumulative incidence of SARS-CoV-2 positivity, COVID-19 hospitalizations, and COVID-19 deaths. For outcome predictors, logistic regression models were developed. Results Of 231 796 patients with diabetes mellitus type 2 in the database, 7 539 were T2DM-CKD (3.25%). The 2-year cumulative incidences of all three studies’ outcomes were higher in T2DM-CKD than in diabetes patients without CKD (positivity 18.1% vs. 14.4%; hospitalization 9.7% vs. 4.2%; death 3.3% vs. 1.1%, all p
Læs mere Tjek på PubMedLaura A. Bray, Lori L. Jervis, Amanda E. Janitz, Laura Ross, Gloria Tallbull, Timothy M. VanWagoner, the CATCH-UP Vaccines Team
PLoS One Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
by Laura A. Bray, Lori L. Jervis, Amanda E. Janitz, Laura Ross, Gloria Tallbull, Timothy M. VanWagoner, the CATCH-UP Vaccines Team Prior research identifies trust as critical to increase vaccine acceptance and uptake. However, few intervention studies have sought to develop or test strategies for bolstering vaccine-related trust. To address this gap, this exploratory study identifies features of COVID-19 vaccine hesitancy interventions that can promote or undermine trust across three interconnected domains: institutional, interpersonal, and product (the vaccine itself). We draw on focus groups (N = 27 participants) with community and university partners involved with hosting COVID-19 testing and vaccine events in underserved Oklahoma communities. Focus groups explored participants’ experiences serving community health needs and elicited feedback on proposed vaccine hesitancy interventions. Proposed interventions included two technology-based strategies (text message reminders and tablet-based testimonials and education) and one dialogue-based strategy (anti-body test interpretation). We find that community partners perceived local universities as trustworthy institutions because of their association with popular sports programs, academic credentials, and proximity, creating opportunities to address vaccine-related distrust through community-university partnerships. The most promising intervention strategies for building interpersonal trust included engaging in one-on-one dialogue and using autonomy enhancing approaches. Finally, interventions that successfully encouraged vaccine trust did so by incorporating personalized health information about individuals’ potential level of protection and susceptibility to the COVID-19 virus. These findings can inform future public health efforts to create trustworthy vaccine hesitancy interventions.
Læs mere Tjek på PubMedMonique Matsuda, Rafael André da Silva, Vinicius Moraes de Paiva Roda, Mônica Valéria Marquezini, Mário Luiz Ribeiro Monteiro, Dânia Emi Hamassaki
PLoS One Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
by Monique Matsuda, Rafael André da Silva, Vinicius Moraes de Paiva Roda, Mônica Valéria Marquezini, Mário Luiz Ribeiro Monteiro, Dânia Emi Hamassaki Anti-VEGF (vascular endothelial growth factor) drugs such as aflibercept (AFL) and bevacizumab (BVZ) inhibit pathological neo-angiogenesis and vascular permeability in retinal vascular diseases. As cytokines and growth factors are produced by Müller glial cells under stressful and pathological conditions, we evaluated the in vitro effect of AFL (Eylea®, 0.5 mg/mL) and BVZ (Avastin®, 0.5 mg/mL) on cell viability/metabolism, and cytokine/growth factor production by Müller cells (MIO-M1) under cobalt chloride (CoCl2)-induced hypoxia after 24h, 48h and 72h. Cell viability/metabolism were analyzed by Trypan Blue and MTT assays and cytokine/growth factors in supernatants by Luminex xMAP-based multiplex bead-based immunoassay. Cell viability increased with AFL at 48h and 72h and decreased with BVZ or hypoxia at 24h. BVZ-treated cells showed lower cell viability than AFL at all exposure times. Cell metabolism increased with AFL but decreased with BVZ (72h) and hypoxia (48h and72h). As expected, AFL and BVZ decreased VEGF levels. AFL increased PDGF-BB, IL-6 and TNF-α (24h) and BVZ increased PDGF-BB (72h). Hypoxia reduced IL-1β, -6, -8, TNF-α and PDGF-BB at 24h, and its suppressive effect was more prominent than AFL (EGF, PDGF-BB, IL-1β, IL-6, IL-8, and TNF-α) and BVZ (PDGF-BB and IL-6) effects. Hypoxia increased bFGF levels at 48h and 72h, even when combined with anti-VEGFs. However, the stimulatory effect of BVZ predominated over hypoxia for IL-8 and TNF-α (24h), as well as for IL-1β (72h). Thus, AFL and BVZ exhibit distinct exposure times effects on MIO-M1 cells viability, metabolism, and cytokines/growth factors. Hypoxia and BVZ decreased MIO-M1 cell viability/metabolism, whereas AFL likely induced gliosis. Hypoxia resulted in immunosuppression, and BVZ stimulated inflammation in hypoxic MIO-M1 cells. These findings highlight the complexity of the cellular response as well as the interplay between anti-VEGF treatments and the hypoxic microenvironment.
Læs mere Tjek på PubMedTijan Jobarteh, Jacob Otu, Ensa Gitteh, Francis S. Mendy, Tutty Isatou Faal-Jawara, Boatema Ofori-Anyinam, Binta Sarr, Abi Janet Riley, Abigail Ayorinde, Bouke C. de Jong, Beate Kampmann, Ousman Secka, Florian Gehre
PLoS One Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
by Tijan Jobarteh, Jacob Otu, Ensa Gitteh, Francis S. Mendy, Tutty Isatou Faal-Jawara, Boatema Ofori-Anyinam, Binta Sarr, Abi Janet Riley, Abigail Ayorinde, Bouke C. de Jong, Beate Kampmann, Ousman Secka, Florian Gehre Background Mycobacterium tuberculosis culturing remains the gold standard for laboratory diagnosis of tuberculosis. Tuberculosis remains a great public health problem in developing countries like The Gambia, as most of the methods currently used for bacterial isolation are either time-consuming or costly. Objective To evaluate the Kudoh swab method in a West African setting in Gambia, with a particular focus on the method’s performance when culturing Mycobacterium africanum West Africa 2 (MAF2) isolates. Method 75 sputum samples were collected in the Greater Banjul Area and decontaminated in parallel with both the standard N-acetyl-L-Cysteine-NaOH (NALC-NaOH) and the Kudoh swab method in the TB diagnostics laboratory in the Medical Research Council Unit The Gambia between 30th December 2017 and 25th February 2018. These samples were subsequently cultured on standard Löwenstein-Jensen and Modified Ogawa media respectively and incubated at 37°C for mycobacterial growth. Spoligotyping was done to determine if the decontamination and culture methods compared could equally detect Mycobacterium tuberculosis, Mycobacterium africanum West Africa 1 and Mycobacterium africanum West Africa 2. Result Among the 50 smear positives, 35 (70%) were culture-positive with Kudoh and 32 (64%) were culture positive with NALC-NaOH, whilst 7(28%) of the 25 smear negative samples were culture positive with both methods (Table 2). There was no significant difference in recovery between both methods (McNemar’s test, p-value = 0.7003), suggesting that the overall positivity rate between the two methods is comparable. There were no differences in time-to-positivity or contamination rate between the methods. However, Kudoh yielded positive cultures that were negative on LJ and vice versa. All findings were irrespective of mycobacterial lineages. Conclusion The Kudoh method has comparable sensitivity to the NALC-NaOH method for detecting Mycobacterium tuberculosis complex isolates. It is easy to perform and could be an add on option for mycobacterial culture in the field in The Gambia, since it requires less biosafety equipment.
Læs mere Tjek på PubMed